Research programme: purinoceptor P2X3 antagonists - NEOMED

Drug Profile

Research programme: purinoceptor P2X3 antagonists - NEOMED

Alternative Names: BLU-5937; NEO-5024; NEO-5937; P2X3 receptor antagonists - NEOMED

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer NEOMED
  • Class Small molecules
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cough; Pain; Visceral pain
  • No development reported Interstitial cystitis

Most Recent Events

  • 07 Mar 2017 Preclinical trials in Pain in Canada (PO), before March 2017 (NEOMED website)
  • 07 Mar 2017 Preclinical trials in Visceral pain in Canada (PO), before March 2017 (NEOMED website)
  • 28 Feb 2017 Preclinical trials in Cough in Canada (PO), before February 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top